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Abstract
Introduction: A subgroup of patients with primary Sjögren’s Syndrome (SS) and positive anticentromere
antibodies (ACA) were recognized as having features intermediate between SS and systemic sclerosis (SSc). Our
goal was to describe this group clinically and serologically and define its tendency to evolve to full blown SSc.
Methods: Among 535 patients with primary SS we identified 20 ACA positive (ACA+/SS). We compared them to
61 randomly selected ACA negative SS patients (ACA-/SS), 31 ACA positive SSc patients with sicca manifestations
[SSc/(+) sicca] and 20 ACA positive SSc patients without sicca manifestations [SSc/(-) sicca].
Results: Prevalence of ACA among SS patients was 3.7%. Cases and controls did not differ in sex ratio and age at
disease onset. ACA+/SS patients had a lower prevalence of dry eyes, hypergammaglobulinaemia, anti-Ro and anti-
La antibodies and a higher prevalence of Raynaud’s phenomenon and dysphagia compared to ACA-/SS patients.
They also had lower prevalence of telangiectasias, puffy fingers, sclerodactyly, Raynaud’s phenomenon, digital
ulcers and gastroesophageal reflux in comparison to both of the SSc subgroups and a lower prevalence of
dyspnoea and lung fibrosis compared to the SSc/(+) sicca subgroup. Two patients originally having ACA+/SS
evolved to full blown SSc. Four deaths occurred, all among SSc patients. Kaplan Meier analysis showed a significant
difference between cases and controls in time from disease onset to development of gastroesophageal reflux,
telangiectasias, digital ulcers, arthritis, puffy fingers, xerostomia, hypergammaglobulinaemia and dysphagia.
Conclusions: ACA+/SS has a clinical phenotype intermediate between ACA-/SS and SSc and shows little tendency
to evolve to SSc.
Introduction
Sjögren’s Syndrome (SS) is a chronic autoimmune dis-
ease characterized by lymphocytic infiltration of the exo-
crine glands. It can present both with glandular and
extraglandular manifestations [1,2] and may be either
primary or associated with other rheumatic diseases. In
approximately 60% of cases SS develops secondarily to
other autoimmune conditions, most commonly rheuma-
toid arthritis, systemic lupus erythematosus or systemic
sclerosis (SSc), while among those with various other
systemic autoimmune diseases SS has a prevalence of
20% [1,3]. A subset of patients with primary disease,
who present features intermediate between SS and lim-
ited cutaneous SSc has been previously recognized [4-6].
Their common characteristic is the finding of anticen-
tromere antibodies (ACA) detected by immunofluores-
cence on Hep-2 cells. It remains to be answered
whether these ACA positive SS patients represent
merely a SS subgroup or if they constitute a transitional
phase in the evolution to full blown SSc. Our goal was
to clinically and immunologically characterize ACA
positive SS patients in comparison to both ACA nega-
tive SS patients and ACA positive SSc patients, and to
determine their tendency to evolve to definite SSc.
Materials and methods
Patients
We retrospectively studied the charts of 535 SS patients
seen in our outpatient clinic between 1981 and 2009.
Amongst them we identified 20 ACA positive patients
(ACA+/SS), who fulfilled the American-European con-
sensus criteria for the classification of SS [7]. Our
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selected from the pool of ACA negative SS patients
(ACA-/SS) (1 out of every nine patients) and another 51
ACA positive SSc patients, divided in two subgroups
depending on the presence (SSc/(+) sicca, n = 31) or
absence (SSc/(-) sicca, n = 20) of concomitant sicca
manifestations. Twelve SSc patients in the first subgroup
fulfilled criteria for secondary SS according to the
American European consensus group criteria. Diagnosis
of SSc was based on the preliminary classification cri-
teria of the American Rheumatism Association [8] and
the criteria for classification of early SSc, proposed by
LeRoy and Medsger in 2001 [9]. Patients satisfying cri-
teria for prescleroderma or very early SSc, as recently
put forward by the European League Against Rheuma-
tism Scleroderma Trials and Research Group (EUSTAR)
[ 1 0 ] ,w e r en o ti n c l u d e di nt h eS S cg r o u p ,s i n c eo u r
main goal was to examine progression of ACA+/SS
patients to definite SSc. The design of our study was
approved by the Laikon Hospital Ethics Committee and
written informed consent was obtained from all partici-
pants or from the first degree relatives of those
deceased.
Data collection
For every study participant we collected demographic,
clinical and immunological data, both at first visit and
cumulatively over the entire follow up period. Disease
onset was defined by the appearance of Raynaud’sP h e -
nomenon, sicca manifestations, salivary gland enlarge-
ment, arthritis, purpura, puffy fingers, sclerodactyly,
digital ulcers, calcinosis, dysphagia, gastroesophageal
reflux, pulmonary arterial hypertension or lung fibrosis.
Table 1 presents the first disease symptom by disease
category. Abnormal findings in minor salivary gland
biopsy, Schirmer test and Rose Bengal stain were
defined as elsewhere described [7,11]. Tear film break
up time of less than 10 seconds and subjective com-
plaints of dry eyes, xerostomia, dyspnoea and dysphagia
were additionally documented. Salivary gland
enlargement, lymphadenopathy, arthritis, purpura, telan-
giectasias, puffy fingers, digital ulcers, Raynaud’sp h e -
nomenon, calcinosis and sclerodactyly were recorded as
assessed by the attending physician. Diagnosis of gastro-
esophageal reflux was based on clinical symptoms of
heartburn and regurgitation, further confirmed by gas-
troscopy [12]. If a right heart catheterization had not
been performed, the diagnosis of pulmonary arterial
hypertension was made by heart Doppler echocardiogra-
phy, using a pulmonary artery systolic pressure (PASP)
= 40 mmHg as a cutoff, since values above this were
shown in a SSc cohort to predict more accurately the
finding of pulmonary arterial hypertension in cardiac
catheterization [13]. Lung fibrosis was documented by
chest x-ray and when needed by high resolution com-
puted tomography, allowing identification of ground
glass opacities. Serositis (pleuricy or pericarditis) was
diagnosed radiologically or echocardiographically.
Recognition of a restrictive pattern on pulmonary func-
tion tests required a reduction of total lung capacity
below 75% of the predicted value, or the combination of
a forced vital capacity (FVC) below 75% of the predicted
value and a normal or above normal forced expiratory
volume in first second (FEV1)/FVC ratio. Peripheral
neuropathy was diagnosed by neurophysiologic testing.
Carpal tunnel syndrome was documented based on the
recommendations of the National Institute of Occupa-
tional Safety and Health [14]. Renal involvement was
defined by the development of acute onset hypertension
and elevated serum creatinine or impaired creatinine
clearance (<60 ml/minute), elevated urinary pH (>6),
p r o t e i n u r i a( > 3 0 0m g / d a y )o rt h ep r e s e n c eo fa c t i v e
urine sediment. Regarding laboratory tests, white blood
cell count <4 K/μL, C3 <75 mg/dl, C4 <10 mg/dl, rheu-
matoid factor >20 I U/ml and g-globulin >1.7 g/dl were
considered abnormal. For the diagnosis of primary bili-
ary cirrhosis and autoimmune hepatitis the criteria
described elsewhere were used [15,16]. The diagnosis of
celiac and atrophic gastritis required serological or his-
tological evidence [17,18]. Hashimoto was diagnosed on
the grounds of clinical or subclinical hypothyroidism
and positive anti-thyroid peroxidase and/or anti-thyro-
globulin antibodies [19]. Diagnosis of lymphoma
required histological confirmation.
Statistical analysis
We compared patients’ characteristics between the ACA
+/SS and each of the control groups, using Pearson’s c
2
test, Fisher’s exact test and one way analysis of variance
Table 1 First symptom by disease category.
First symptom Disease category
ACA+/SS
(n = 20)
[%]
SSc/(-)
sicca
(n = 20)
[%]
SSc/(+)
sicca
(n = 31)
[%]
ACA-/SS
(n = 61)
[%]
Raynaud
phenomenon
6 [30.00] 18 [90.00] 29 [93.55] 5 [8.20]
sicca manifestations 15 [75.00] - 6 [19.35] 52 [85.25]
SGE 1 [5.00] - 1 [3.23] 12 [19.67]
arthritis 1 [5.00] 1 [5.00] 2 [6.45] 4 [6.56]
purpura, - - - 4 [6.56]
puffy fingers/
sclerodactyly
1 [5.00] 6 [30.00] 8 [25.81] 4 [6.56]
digital ulcers - 2 [10.00] 1 [3.23] -
dysphagia/GER 1 [5.00] 1 [5.00] 1 [3.23] -
lung fibrosis - - - 1 [1.64]
Some patients reported more than one initial symptom. SGE, salivary gland
enlargement, GER, gastroesophageal reflux
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cated. Two-sided probability (P) values < 0.05 were con-
sidered statistically significant. Median time from
disease onset to death or to development of particular
clinical symptoms and laboratory findings was derived
from Kaplan Meier curves and tested for statistical sig-
nificance by the log-rank statistic. The Statistical Pack-
age for the Social Sciences (version 17, SPSS Inc.,
Chicago, Illinois, USA) was used for the analysis.
Results
Demographics, follow-up and disease duration of cases
and controls
Of the 535 SS patients in our cohort, 20 were ACA
positive, corresponding to a prevalence of 3.7%. All
patients in this group were female, with an age at dis-
ease onset of 52.35 ± 3.35 years [mean ± standard error
(SE)]), disease duration of 12.13 ± 1.65 years (mean ±
SE) and a follow up of 5.38 ± 1.15 years (mean ± SE).
As seen in Table 2, these variables did not differ signifi-
cantly between cases and controls. Moreover, cases and
controls did not differ with regard to sex ratio or smok-
ing habits (Table 3).
Immunological profile and histological findings of cases
and controls
Anti-Ro/SS-A and anti-La/SS-B autoantibodies were
detected in 30% and 15% of ACA+/SS patients, com-
pared to 70.5% (P = 0.003) and 41% (P = 0.056) of
ACA-/SS patients, respectively. The SSc/(+) sicca group
did not differ significantly from the ACA+/SS group in
the prevalence of anti-Ro/SS-A and anti-La/SS-B auto-
antibodies, while SSc/(-) sicca patients displayed neither
anti-Ro/SS-A nor anti-La/SS-B reactivity in their sera.
Other autoantibodies such as anti-U1RNP, anti-Sm and
anti-Scl70 occurred rarely and their prevalence did not
differ significantly between groups (Table 3).
Minor salivary gland biopsy had been performed in 19
ACA+/SS patients, 57 ACA-/SS patients and 16 SSc/(+)
sicca patients, resulting in an equal frequency (94.7%) of
abnormal findings in the two SS groups, and a some-
what lower frequency in the SSc/(+) sicca subgroup
(75%), although this difference was not significant. Simi-
larly, cases and controls undergoing ocular examination
with Rose Bengal stain, Schirmer test and tear film
break up time had a comparable prevalence of abnormal
results (Table 4).
Table 2 Age at disease onset, disease duration and duration of follow up of cases and controls
Disease Characteristics
Age at first symptom (P = 0.108)
a Age at first non-Raynaud symptom
(P = 0.279)
a
Mean SD Mean difference (P-value)
b Mean SD Mean difference (P-value)
b
ACA+/SS (n = 20) 52.35 15.0 53.55 15.2
SSc/(+) sicca (n = 31) 43.29 15.8 0.187 47.23 13.2 0.699
SSc/(-) sicca (n = 20) 42.45 15.5 0.196 47.3 15.7 0.954
ACA-/SS (n = 61) 46.52 13.31 0.729 46.6 13.3 0.341
Disease duration from onset of first symptom
(P < 0.0001)
a
Disease duration from onset of first non-Raynaud symptom
(P = 0.036)
a
Mean SD Mean difference (P-value)
b Mean SD Mean difference (P-value)
b
ACA+/SS (n = 20) 12.13 7.4 10.96 7.0
SSc/(+) sicca (n = 31) 17.51 11.1 0.248 13.48 6.7 1.000
SSc/(-) sicca (n = 20) 15.99 11.7 1.000 11.20 8.6 1.000
ACA-/SS (n = 61) 8.89 7.4 1.000 8.78 7.3 1.000
Duration of Follow up (P = 0.012)
a -
Mean SD Mean difference (P-value)
b -
ACA+/SS (n = 20) 5.38 5.1 -
SSc/(+) sicca (n = 31) 7.87 5.2 0.494 -
SSc/(-) sicca (n = 20) 4.00 4.1 1.000 -
ACA-/SS (n = 61) 4.49 5.0 1.000 -
a. overall P from ANOVA
b. Difference in mean when compared with group ACA (+) SS.
Data were calculated using both the first symptom and the first non Raynaud symptom as a starting point.
Bournia et al. Arthritis Research & Therapy 2010, 12:R47
http://arthritis-research.com/content/12/2/R47
Page 3 of 10Clinical and laboratory features of cases and controls
Differences in the prevalence of clinical and laboratory
characteristics of cases and controls were detected
already at first visit and, as a general rule, they per-
sisted or became even more pronounced, when the
entire follow up period was considered. More specifi-
cally for the entire follow up period, telangiectasias,
puffy fingers, sclerodactyly, Raynaud’s phenomenon,
digital ulcers and gastroesophageal reflux were signifi-
cantly less frequent among ACA+/SS patients as com-
pared to both SSc subgroups. The ACA+/SS group
also had a lower prevalence of dyspnoea (P =0 . 0 4 9 )
and lung fibrosis (P = 0.029) in comparison to
the SSc/(+) sicca group. Compared to ACA-/SS, ACA
+/SS patients were less prone to develop dry eyes
(P = 0.045), but more inclined to develop Raynaud’s
phenomenon (P = 0.0001) or dysphagia (P = 0.004).
Dyspnoea and digital ulcers were also more prominent
in the ACA+/SS group, but not at a statistically signifi-
cant level (Table 4).
Among those having undergone a pulmonary function
test, a restrictive pattern was seen in 22.2% of ACA+/SS
patients as compared to 30.8% of SSc/(+) sicca patients
(P = 1.000), 42.9% of SSc/(-) sicca patients (P = 0.400)
and none of the ACA-/SS patients (P =0 . 2 1 1 ) .O n l ya
small proportion of patients in each group had done a
chest high resolution computed tomography, on the
basis of a previous chest x-ray marginally indicative of
an interstitial pattern. Although small numbers do not
allow for safe conclusions, no statistically significant
Table 3 Patients’ demographics, autoimmune profile and co-morbidities by disease category
Characteristics of patients (P-value
1) ACA+/SS
(n = 20) [%]
SSc/(+) sicca
(n = 31) [%]
SSc/(-) sicca (n = 20) [%] ACA-/SS
(n = 61) [%]
Sex(0.558)
female 20 [100.0] 28 [90.3] 19 [95.0] 57 [93.4]
male 0 [0.0] 3 [9.7] 1 [5.0] 4 [6.6]
P-values
2 0.271 1.000 0.567
Smoking (0.603) 4 [20.0] 5 [16.1] 2 [10.0] 14 [23.0]
P –values
2 0.703 0.661 1.000
Anti-Ro (<0.0001) 6 [30.0] 4 [12.9] 0 [0.0] 43 [70.5]
P-values
2 0.163 0.020 0.003
Anti-La (<0.0001) 3 [15.0] 2 [6.5] 0 [0.0] 25 [41.0]
P-values
2 0.369 0.231 0.056
ANA (0.006) 20 [100.0] 31 [100.0] 20 [100.0] 51 [83.6]
P-values
2 - - 0.060
Anti-U1RNP (0.558) 0 [0.0] 3 [9.7] 1 [5.0] 4 [6.6]
P-values
2 0.271 1.000 0. 567
Anti-Sm (0.721) 0 [0.0] 1 [3.2] 0 [0.0] 2 [3.3]
P-values
2 1.000 - 1.000
Anti-Scl70 (0.172) 0 [0.0] 2 [6.5] 1 [5.0] 0 [0.0]
P-values
2 0.514 1.000 -
Th. Hashimoto (0.023) 1 [5.0] 4 [12.9] 0 [0.0] 15 [24.6]
P-values
2 0.636 1.000 0.102
Autoim. Hepatitis (-) 0 [0.0] 0 [0.0] 0 [0.0] 0 [0.0]
P-values
2 ---
Atr. gastritis (0.422) 2 [10.0] 2 [6.5] 0 [0.0] 2 [3.3]
P-values
2 0.640 0.487 0.254
PBC (0.209) 3 [15.0] 3 [9.7] 0 [0.0] 3 [4.9]
P-values
2 0.668 0.231 0.157
Celiac (0.209) 0 [0.0] 0 [0.0] 0 [0.0] 1 [1.6]
P-values
2 - - 1.000
Lymphoma (0.476) 0 [0.0] 2 [6.5] 0 [0.0] 2 [3.3]
P-values
2 0.514 - 1.000
Death (0.059) 0 [0.0] 3 [9.7] 1 [5.0] 0 [0.0]
P-values
2 0.271 1.000 -
1 Overall P-value from the Chi Square test of independence (significance < 0.05).
2 P-values from the Fisher’s exact test comparing the first group with each of the other three groups
PBC, primary biliary cirrhosis
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Page 4 of 10Table 4 Patients’ clinical characteristics by disease category, cumulatively for the entire follow up period
Characteristics of patients
(P-value
1)
ACA+/SS
(n = 20) [%]
SSc/(+) sicca
(n = 31) [%]
SSc/(-) sicca
(n = 20) [%]
ACA-/SS
(n = 61) [%]
Positive MSGB (0.039) 18 [94.7] 12 [75.0] - 54 [94.7]
P-values
2 0.156 1.000
Abnormal Rose Bengal (0.364) 8 [72.7] 9 [56.3] 0 [0.0] 22 [71.0]
P-values
2 0.448 0.333 1.000
Abnormal Schirmer test (0.176) 9 [64.3] 14 [87.5] 0 [0.0] 35.5 [71.4]
P-values
2 0.204 0.400 0.743
Abnormal BUT (0.428) 7 [77.8] 9 [75.0] 0 [0.0] 18 [69.2]
P-values
2 1.000 0.300 1.000
Lymphadenopathy (0,249) 3 [15.0] 8 [25.8] 1 [5.0] 9 [14.8]
P-values
2 0.493 0.605 1.000
Raynaud (<0.0001) 15 [75.0] 31 [100.0] 20 [100.0] 11 [18.0]
P-values
2 0.007 0.047 <0.0001
SGE (0.006) 3 [15.0] 4 [12.9] 0 [0.0] 20 [32.8]
P-values
2 1.000 0.231 0.160
Purpura (0,052) 2 [10.0] 1 [3.2] 0 [0.0] 11 [18.0]
P-values
2 0.553 0.487 0.502
Xerostomia (<0.0001) 19 [95.0] 25 [80.6] 0 [0.0] 53 [86.9]
P-values
2 0.223 <0.0001 0.440
Dry eyes (<0.0001) 17 [85.0] 29 [93.5] 0 [0.0] 60 [98.4]
P-values
2 0.369 <0.0001 0.045
Telangiectasias (<0.0001) 2 [10.0] 28 [90.3] 14 [70.0] 2 [3.3]
P-values
2 <0.0001 <0.0001 0.254
Puffy fingers (<0.0001) 7 [35.0] 26 [83.9] 14 [70.0] 10 [16.4]
P-values
2 0.001 0.056 0.112
Sclerodactyly (<0.0001) 0 [0.0] 31 [100.0] 19 [95.0] 0 [0.0]
P-values
2 <0.0001 <0.0001 -
Calcinosis (0. 001) 0 [0.0] 6 [19.4] 4 [20.0] 0 [0.0]
P-values
2 0.070 0.106 -
Ulcers (0.249) 2 [10.0] 17 [54.8] 11 [55.0] 0 [0.0]
P-values
2 0.001 0.006 0.059
Dysphagia (<0.0001) 7 [35.0] 18 [58.1] 5 [25.0] 4 [6.6]
P-values
2 0.153 0.731 0.004
GER (<0.0001) 3 [15.0] 20 [64.5] 10 [50.0] 6 [9.8]
P-values
2 0.001 0.041 0.682
Arthritits (0.372) 8 [35.0] 10 [32.3] 4 [20.0] 14 [23.0]
P-values
2 0.765 0.301 0.156
Dyspnoea (<0.0001) 7 [40.0] 20 [64.5] 5 [25.0] 9 [14.8]
P-values
2 0.049 0.731 0.060
PAH (0.004) 2 [10.0] 8 [25.8] 2 [10.0] 1 [1.6]
P-values
2 0.280 1.000 0.149
Ground glass HRCT (0.606) 0 [0.0] 4 [21.1] 1 [9.1] 1 [12.5]
P-values
2 0.544 1.000 1.000
Lung fibrosis (0.001) 2 [10.0] 12 [38.7] 7 [35.0] 5 [8.2]
P-values
2 0.029 0.127 1.000
Restrict. pattern PFTs (0.103) 2 [22.2] 8 [30.8] 6 [42.9] 0 [0.0]
P-values
2 1.000 0.400 0.211
Serositis (0.080) 3 [15.0] 6 [19.4] 3 [15.0] 2 [3.3]
P-values
2 1.000 0.019 0.094
Renal involvement (0.760) 0 [0.0] 0 [0.0] 0 [0.0] 1 [1.6]
P-values
2 -- 1.000
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pattern between ACA+/SS patients and controls.
When comparing cases to controls with reference to
laboratory findings, no statistically significant differences
were observed, with the exception of hypergammaglobu-
linaemia, which tended to be more frequent in the
ACA-/SS compared to the ACA+/SS group (P =0 . 0 6 8 ) .
None of the patients in any of the groups had protei-
nuria (Table 4).
Prevalence of co-morbidities in cases and controls
Thyroiditis Hashimoto affected 5% of ACA+/SS patients,
compared to 24.6% of ACA-/SS patients (P = 0.102) and
12.9% of SSc/(+) sicca patients (P = 0.636). For primary
biliary cirrhosis (PBC) the respective proportions were
1 5 % ,a sc o m p a r e dt o4 . 9 %( P = 0.157) and 9.7% (P =
0.668), while the prevalence for atrophic gastritis was
10%, compared to 3.3% (P = 0.254) and 6.5% (P = 0.640)
respectively. None of the SSc/(-) sicca patients had any
of the above conditions. Differences between cases and
controls were non-significant. Autoimmune hepatitis did
not occur in any of the groups and only one patient in
the ACA-/SS group had celiac (Table 3).
Evolution of ACA+/SS patients
During our follow up period two patients in the ACA-/
SS group and another two in the SSc/(+) sicca subgroup
developed lymphoma, while four patients died, all of
which had SSc. Differences in mortality and lymphoma
development between cases and controls were not sig-
nificant (Table 3).
The overwhelming majority of ACA positive SSc/(+)
sicca patients fulfilled criteria for SSc, already at their
first visit. Of the 31 patients in this group, only two
started out as ACA+/SS to which a diagnosis of SSc was
added, in both cases after one year of follow up. One of
these two patients later developed pulmonary arterial
hypertension and died. Another three patients with Ray-
naud’s phenomenon, puffy fingers, ACA and sicca mani-
festations at first visit eventually developed SSc, after 3,
9 and 24 months respectively, but never fulfilled criteria
for SS.
Time to development of particular symptoms
Distribution of time from disease onset to development
of certain clinical features was examined for the four
groups of patients. In comparison to the ACA+/SS
group, telangiectasias, digital ulcers and gastroesopha-
geal reflux tended to occur sooner in the SSc sub-
groups, finally affecting these groups almost entirely.
Puffy fingers developed sooner and xerostomia devel-
oped later in the SSc/(+) sicca compared to the ACA
+SS group. Regarding development of arthritis, it
occurred later in the SSc/(-) sicca subgroup compared
to the ACA+/SS group. Likewise, when comparing
ACA+/SS to ACA-/SS patients, dysphagia appeared
earlier in the first group while hypergammaglobulinae-
mia in the second group. Statistics for survival curves
depicting time to death or to development of sclero-
dactyly and calcinosis could not be calculated since all
cases in the ACA+/SS and ACA-/SS groups were cen-
sored (Figure 1).
Table 4: Patients’ clinical characteristics by disease category, cumulatively for the entire follow up period (Continued)
Carpal tunnel (0.853) 2 [10.0] 3 [9.7] 3 [15.0] 5 [4.9]
P-values
2 1.000 1.000 1.000
Per. Neuropathy (0.743) 1 [5.0] 2 [6.5] 0 [0.0] 3 [86.9]
P-values
2 1.000 1.000 1.000
Leucopenia (0,088) 2 [10.0] 2 [6.5] 2 [10.0] 15 [24.6]
P-values
2 0.640 1.000 0.216
Hypergammaglobulinaemia (0.0001) 5 [25.0] 6 [19.4] 1 [5.0] 31 [50.8]
P-values
2 0.732 0.182 0.068
Cryoglobulinaemia (0.609) 0 [0.0] 2 [6.5] 1 [5.0] 5 [4.9]
P-values
2 0.514 1.000 0.326
RF (0.015) 5 [25.0] 6 [19.4] 4 [20.0] 29 [47.5]
P-values
2 0.732 1.000 0.117
Low C3,C4 (0.289) 0 [0.0] 5 [20.0] 3 [23.1] 10 [19.6]
P-values
2 0.137 0.087 0.101
Proteinuria (0.760) 0 [0.0] 0 [0.0] 0 [0.0] 1 [1.6]
P-values
2 -- 1.000
1 Overall P-value from the Chi Square test of independence (significance < 0.05).
2 P-values from the Fisher’s exact test comparing the first group with each of the other three groups MSGB: minor salivary gland biopsy, BUT, Tear film break up
time, SGE, salivary gland enlargement, GER, gastroesophageal reflux, PAH, pulmonary arterial hypertension, HRCT, high resolution computed tomography, PFT,
pulmonary function tests, RF, rheumatoid factor
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In an earlier, retrospective, study of 41 ACA positive
patients a prevalence of 17% was reported for primary
SS, thus for the first time establishing an association
between ACA and primary SS [6]. This finding was cor-
roborated by other investigators who showed that the
prevalence of primary SS in different ACA positive
cohorts ranged from 2.5% to 12% [4,20-24]. Our present
goal was to focus on the clinical and serological charac-
teristics and on the outcome of ACA/+SS patients, after
a long follow up.
In our study, ACA were found in 3.7% of patients with
SS, which is in agreement with some reports estimating
this prevalence in the range of 4.5% to 8.7% [5,25], but
Figure 1 Kaplan Meier analysis. Kaplan Meier curves for time to development of Gastroesophageal reflux (GER), dysphagia, arthritis,
telangiectasias, digital ulcers, puffy fingers, xerostomia, and hypergammaglobulinaemia. The X axis depicts time in years from the presentation of
the first symptom.
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reported by Katano et al (24.6%) [26], Chan et al.
(14.8%) [24] or Caramaschi et al. (16.6%) [27].
In accordance to previous studies [5,26,28] all of our
groups demonstrated a striking female preponderance.
Our findings, however, do not corroborate those of
other investigators [5,26,28], reporting a higher mean
age at disease onset in the ACA+/SS, compared to the
ACA/-SS group.
We and other researchers [5,6,27,28] have shown a
significantly lower prevalence of anti-Ro/SS-A and anti-
La/SS-B autoantibodies among ACA+/SS compared to
ACA-/SS patients. As expected, anti-Ro/SS-A and anti-
La/SS-B autoantibodies were absent in the SSc/(-) sicca
subgroup. However, their prevalence in the SSc/(+) sicca
subgroup was similar to that found in the ACA+/SS
group, indicating that, with respect to immunological
profile, ACA+/SS displays features of an overlap
between SS and SSc. Contrary to others [27-29], we
didn’t find significantly lower rates of rheumatoid factor
positivity in the ACA+/SS compared to the ACA-/SS
group. In addition, previous reports have detected auto-
antibodies other than ACA, anti-Ro/SS-A, anti-La/SS-B
and rheumatoid factor in more than 50% of ACA+/SS
patients [5], whereas in our study none of the patients
in this group presented anti-Scl 70, anti-U1RNP or anti-
Sm autoantibodies. As shown in a previous publication,
anti-Sm and anti-U1RNP are rare in Greek patients,
even among those who suffer from systemic lupus
erythematosus [30].
An association of ACA positive SS with primary bili-
ary cirrhosis has been established in previous works [5],
but was not seen in our cohort. Organ specific autoim-
mune diseases affecting our group of ACA+/SS patients
encompassed primary biliary cirrhosis (15%), Hashimoto
thyroiditis (5%) and atrophic gastritis (10%), but differ-
ences in prevalence between this group and the controls
were not significant.
Our findings corroborate previous works that report a
greater frequency of Raynaud’s phenomenon [5,26,27]
and a significantly lower frequency of hypergammaglo-
bulinaemia [27,28] in patients with ACA+/SS compared
to patients with ACA-/SS. However, in contrast to
Katano et al. [26] and Caramashi et al. [27] we did not
observe a lower prevalence of leucocytopenia in our
group of ACA+/SS and found no difference in the fre-
quency of peripheral neuropathy between cases and
ACA-/SS controls, although contradictory reports exist
on this issue [5,28].
Given that patients are likely to develop symptoms
compatible with a lcSSc diagnosis not all at once, but
gradually over time [31] there is a probability that ACA
+/SS patients will eventually develop SSc in the long
run. However, the lower prevalence we found for
calcinosis, Raynaud’s phenomenon, esophageal dysmoti-
lity, sclerodactyly, telangiectasias, puffy fingers, digital
ulcers and lung fibrosis in the ACA+/SS group com-
pared to the SSc subgroups, combined with an equal
follow up duration of cases and controls, makes this
evolutionary pattern unlikely. Only two patients that ori-
ginally started out as ACA+/SS, developed symptoms
compatible with a SSc diagnosis later during their follow
up. In contrast, the majority of ACA+/SS patients retain
during the course of their disease a clinical pattern dis-
tinct from both the ACA-/SS and the SSc groups.
There are previous reports of ACA+/SS patients hav-
ing evolved to SSc. Caramashi et al[27] described four
such cases out of a total of ten and Ramos-Casals et al.
[25] additionally reported another three out of an initial
group of eight. In the study performed by Salliot et al.
[5] none of the 10 ACA+/SS patients advanced to lcSSc,
while according to Miyawaki et al. [4] their cohort of 84
ACA positive SSc patients included six patients, who
originally had primary SS and Raynaud’sp h e n o m e n o n
before developing lcSSc. In total, counting in the two
cases from our cohort, 15 out of 66 patients (23%) initi-
ally presenting with ACA+/SS eventually developed SSc.
Patients with SS are at a higher risk than the general
population for lymphoma development, demonstrating a
standardized incidence rate of 18.9 (95% CI (9.4 to
37.9)) [32,33]. Histologically, the mucosa associated lym-
phoid tissue (MALT) subtype of non-Hodgkin lympho-
mas is the most commonly found. Some of the major
risk factors for lymphoma development in SS patients
include parotid gland enlarg e m e n t ,p u r p u r a ,h y p o c o m -
plementemia and cryoglobulinemia [33]. Despite the fact
that in a recently published case report the presence of
ACA antibodies in two pSS patients was associated with
an increased risk for small vessel cutaneous vasculitis,
parotid enlargement, low C4 complement levels, positive
rheumatoid factor and lymphoma [34], none of these
associations were corroborated by our study. On the
contrary and in agreement with a previous report [27],
none of the ACA+/SS patients in our cohort developed
lymphoma. In addition, differences between cases and
controls with respect to mortality or development of
lymphoma were not significant.
Previous studies did not define a gold standard to
effectively predict whether an ACA+/SS patient will
retain the same disease pattern in the future. It seems
that only by long term follow up can this question be
answered. Therefore the time to development of a
symptom could form a basis on which to decide if the
clinical course of ACA positive SS will remain stable. By
means of the Kaplan Meier survival analysis we identi-
fied an earlier development of symptoms compatible
with the diagnosis of SSc in one or both of the SSc sub-
groups, as compared to the ACA+/SS group. This could
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type rather soon, whereas ACA+/SS patients tend to
keep a stable clinical pattern.
A weakness in our study was the retrospective design.
In addition, we cannot rule out the possibility that some
of the differences observed between the patient and con-
trol groups were due to statistical error type I, caused by
multiple comparisons. Furthermore, our control group
of SSc patients with sicca manifestations might not be
homogenous, in the sense that it includes patients with
secondary SS, but also patients for which sicca symp-
toms could possibly be attributed to the presence of
glandular fibrosis [35]. Finally in some cases the number
of patients censored was too big to allow for safe con-
clusions to be drawn from the Kaplan-Meier statistics.
Conclusions
In conclusion, we have found a lower frequency of dry
eyes, hypergammaglobulinaemia, anti-Ro/SS-A and anti-
La/SS-B autoantibodies and a higher frequency of Ray-
naud’s phenomenon and dysphagia in ACA+/SS as com-
pared to ACA-/SS patients. A lower frequency of
calcinosis, Raynaud’s phenomenon, esophageal dysmoti-
lity, sclerodactyly and telangiectasias was also found in
the ACA+/SS group in comparison to ACA positive SSc
patients, both with and without sicca manifestations. In
addition, only two patients in our cohort and less than
one quarter of the ACA+/SS patients described in the
literature eventually advanced to SSc, despite a long fol-
low-up period. Our findings corroborate the results of
previous studies reporting that ACA+/SS patients pre-
sent clinical features intermediate between ACA nega-
tive SS and SSc, while indicating that these patients, in
their majority, tend not to evolve to full blown SSc.
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